Glecaprevir

Major

Glecaprevir Relugolix Orgovyx Explained Increased relugolix exposure Details Glecaprevir Simvastatin Flolipid Explained Increased simvastatin exposure and increased risk of myopathy Details Glecaprevir Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Glecaprevir Atogepant Qulipta Increased atogepant exposure Details Glecaprevir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy and rhabdomyolysis Details Glecaprevir Capmatinib Tabrecta Increased P-gp substrate exposure and an increased risk of increased adverse reactions Details Glecaprevir Cyclosporine Injection Atopica Increased glecaprevir exposure and an increased cycloSPORINE exposure Details Glecaprevir Cyclosporine Ophthalmic Cequa Increased glecaprevir exposure and an increased cycloSPORINE exposure Details Glecaprevir Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Glecaprevir Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Glecaprevir Darolutamide Nubeqa Increased exposure of OATP1B1 or OATP1B3 substrates Details Glecaprevir Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Glecaprevir Finerenone Kerendia Increased finerenone exposure and an increased risk of finerenone-related adverse effects Details Glecaprevir Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Glecaprevir Lenacapavir Injection Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Glecaprevir Lenacapavir Oral Sunlenca Increased P-gp substrate exposure and an increased risk of P-gp substrate-related adverse reactions Details Glecaprevir Leniolisib Joenja Increased OATP1B1/OATP1B3 substrate exposure Details Glecaprevir Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Glecaprevir Lovastatin Altocor® Increased lovastatin exposure and increased risk of myopathy Details Glecaprevir Methylergonovine Methergine Increased methylergonovine exposure Details Glecaprevir Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Glecaprevir Nifedipine Adalat® Increased NIFEdipine exposure Details